[go: up one dir, main page]

SMT201800593T1 - Inibitore per disturbi retinocoroidei - Google Patents

Inibitore per disturbi retinocoroidei

Info

Publication number
SMT201800593T1
SMT201800593T1 SM20180593T SMT201800593T SMT201800593T1 SM T201800593 T1 SMT201800593 T1 SM T201800593T1 SM 20180593 T SM20180593 T SM 20180593T SM T201800593 T SMT201800593 T SM T201800593T SM T201800593 T1 SMT201800593 T1 SM T201800593T1
Authority
SM
San Marino
Prior art keywords
retinochoroid
disorders
inhibitor
retinochoroid disorders
Prior art date
Application number
SM20180593T
Other languages
English (en)
Inventor
Kazuhiro Kimura
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of SMT201800593T1 publication Critical patent/SMT201800593T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00Feeding-bottles in general
    • A61J9/08Protective covers for bottles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM20180593T 2013-05-22 2014-05-21 Inibitore per disturbi retinocoroidei SMT201800593T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013107706 2013-05-22
EP14800477.3A EP3000466B1 (en) 2013-05-22 2014-05-21 Inhibitor for retinochoroidal disorders
PCT/JP2014/002667 WO2014188716A1 (ja) 2013-05-22 2014-05-21 網脈絡膜障害の抑制剤

Publications (1)

Publication Number Publication Date
SMT201800593T1 true SMT201800593T1 (it) 2019-02-28

Family

ID=51933283

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180593T SMT201800593T1 (it) 2013-05-22 2014-05-21 Inibitore per disturbi retinocoroidei

Country Status (23)

Country Link
US (3) US10702502B2 (it)
EP (2) EP3446690B1 (it)
JP (2) JP6407145B2 (it)
KR (1) KR102303316B1 (it)
CN (1) CN105377258B (it)
AU (1) AU2014269762B2 (it)
BR (1) BR112015029114B1 (it)
CA (1) CA2913005C (it)
CY (1) CY1121036T1 (it)
DK (1) DK3000466T3 (it)
ES (2) ES2694831T3 (it)
HK (1) HK1221909A1 (it)
HR (1) HRP20181876T1 (it)
LT (1) LT3000466T (it)
MX (1) MX362239B (it)
PL (1) PL3000466T3 (it)
PT (1) PT3000466T (it)
RS (1) RS58045B1 (it)
RU (1) RU2672057C2 (it)
SI (1) SI3000466T1 (it)
SM (1) SMT201800593T1 (it)
WO (1) WO2014188716A1 (it)
ZA (1) ZA201508940B (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026251B1 (ru) 2010-09-01 2017-03-31 Томас Джефферсон Юниверсити Способ восстановления и регенерации мышц
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
PT3000466T (pt) 2013-05-22 2018-11-27 Univ Yamaguchi Inibidor para distúrbios retinocoroidais
IL317726A (en) 2016-06-08 2025-02-01 Clementia Pharmaceuticals Inc Methods for treating heterotopic genesis
BR112019009929A2 (pt) * 2016-11-16 2019-08-20 Clementia Pharmaceuticals Inc métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE187434T1 (de) 1993-01-11 1999-12-15 Ligand Pharm Inc Selektivitaet fuer retinoid x rezeptoren enthaltende verbindungen
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030125252A1 (en) 2000-03-14 2003-07-03 Underhill T. Michael Compositions and methods for affecting osteogenesis
MXPA03002861A (es) 2000-10-02 2003-07-14 Hoffmann La Roche Nuevos retinoides para tratamiento del enfisema.
PL370361A1 (en) 2001-09-18 2005-05-16 F.Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
WO2003024920A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists ii
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
JP2008533165A (ja) * 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミティド ナノ粒子免疫抑制性化合物の注射可能組成物
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
WO2007037188A1 (ja) 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
KR20070037188A (ko) 2005-09-30 2007-04-04 현대자동차주식회사 자동 변속기에서 유량 제어구조
CA2647275A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2008057933A2 (en) * 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
EA026251B1 (ru) 2010-09-01 2017-03-31 Томас Джефферсон Юниверсити Способ восстановления и регенерации мышц
JP2013538830A (ja) 2010-09-27 2013-10-17 マイクロドース セラピューテクス,インコーポレイテッド 吸入を用いる疾患治療のための方法及び組成物
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
PT3000466T (pt) 2013-05-22 2018-11-27 Univ Yamaguchi Inibidor para distúrbios retinocoroidais

Also Published As

Publication number Publication date
PT3000466T (pt) 2018-11-27
JP2018115221A (ja) 2018-07-26
US20240180873A1 (en) 2024-06-06
MX2015016083A (es) 2016-03-21
EP3000466B1 (en) 2018-08-15
EP3000466A1 (en) 2016-03-30
ES2989991T3 (es) 2024-11-28
JP6749962B2 (ja) 2020-09-02
CN105377258A (zh) 2016-03-02
AU2014269762A1 (en) 2016-01-07
EP3446690C0 (en) 2024-09-11
CA2913005A1 (en) 2014-11-27
US12357613B2 (en) 2025-07-15
LT3000466T (lt) 2019-02-11
KR102303316B1 (ko) 2021-09-23
JP6407145B2 (ja) 2018-10-17
US11730718B2 (en) 2023-08-22
SI3000466T1 (sl) 2019-02-28
DK3000466T3 (en) 2018-11-26
PL3000466T3 (pl) 2019-04-30
JPWO2014188716A1 (ja) 2017-02-23
CA2913005C (en) 2021-08-10
BR112015029114A2 (pt) 2017-07-25
US20210121442A1 (en) 2021-04-29
US10702502B2 (en) 2020-07-07
RU2015154741A (ru) 2017-06-28
EP3446690A1 (en) 2019-02-27
CN105377258B (zh) 2020-08-28
BR112015029114A8 (pt) 2020-03-17
MX362239B (es) 2019-01-09
EP3446690B1 (en) 2024-09-11
ZA201508940B (en) 2017-11-29
US20160120843A1 (en) 2016-05-05
AU2014269762B2 (en) 2019-09-12
BR112015029114B1 (pt) 2020-11-24
RU2672057C2 (ru) 2018-11-09
EP3000466A4 (en) 2017-01-25
NZ715245A (en) 2021-04-30
RS58045B1 (sr) 2019-02-28
ES2694831T3 (es) 2018-12-27
KR20160013075A (ko) 2016-02-03
HRP20181876T1 (hr) 2019-03-08
WO2014188716A1 (ja) 2014-11-27
CY1121036T1 (el) 2019-12-11
HK1221909A1 (zh) 2017-06-16

Similar Documents

Publication Publication Date Title
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HRP20181129T1 (hr) Pirimidin inhibitori fgfr4
SMT201700363T1 (it) Inibitori di bromodominio cristallini
HUE053815T2 (hu) SYK inhibitorok
LT3060041T (lt) Prostaciklino junginiai
LT2841428T (lt) Dnr-pk inhibitoriai
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
ZA201506156B (en) Novel inhibitors
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK2956698T3 (da) Bindestrimler
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2988310A4 (en) CONVERTER
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
ZA201508940B (en) Inhibitor for retinochoroidal disorders
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
EP2958828A4 (de) Spender
DE112014001252A5 (de) Aufbissschiene
EP3060191C0 (en) A dispenser
EP2987416A4 (en) PERFUME Decomposition INHIBITORS
DE112014000270A5 (de) Verteiler
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti